Addictions Therapeutics Global Market Report 2024

The addictions therapeutics market size has grown strongly in recent years. It will grow from $6.56 billion in 2023 to $7.01 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be attributed to several factors, including the increased use of addictive substances such as alcohol, tobacco, and drugs, a growing awareness and prevalence of substance abuse disorders, the legalization of marijuana in various states, and increased funding and support for addiction treatment initiatives. These elements collectively contributed to the expansion of efforts and resources dedicated to addressing addiction-related challenges and promoting treatment and recovery.

The addictions therapeutics market size is expected to see strong growth in the next few years. It will grow to $8.83 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period can be attributed to various factors, including the proliferation of drug awareness campaigns, the emergence of synthetic drugs and new psychoactive substances, changing lifestyles and increased stress factors, the expansion of rehabilitation facilities, and the integration of telehealth services in addiction treatment. Key trends expected in the forecast period encompass technological advancements in diagnostics, neuroscientific advances, partnerships and collaborations between pharmaceutical companies and other stakeholders to address addiction issues, and the launch of innovative drugs for addiction therapeutics. These trends collectively contribute to the evolution and improvement of addiction treatment approaches and solutions.

The projected rise in alcohol consumption stands as a significant driver propelling the growth of the addiction therapeutics market. Alcohol consumption entails the intake of beverages containing ethyl alcohol, and addiction therapeutics aim to address alcohol-related addiction by moderating its depressive effects and reinstating the balance between neurotransmitters. These therapeutics help reduce alcohol cravings, alleviate withdrawal symptoms such as insomnia, anxiety, and restlessness, thereby encouraging reduced alcohol consumption. Notably, a report by Statistics Canada in February 2023 revealed a noteworthy surge in alcoholic beverage sales at retail outlets and liquor authorities, reaching $26.1 billion for the fiscal year ending March 31, 2022 - an increase of 2.4% from the previous year. Wine sales also experienced a 2.1% uptick, reaching $8.1 billion in the same period. Beer constituted 34.9% of total alcohol sales value in 2021–2022, followed by wine at 31.3%, spirits at 25.8%, and ciders and coolers at 8.0%. Consequently, the escalating alcohol consumption is fueling the demand for addiction therapeutics.

The burgeoning healthcare expenditure globally is poised to foster the expansion of the addiction therapeutics market. Healthcare expenditure encompasses the financial resources directed towards healthcare-related goods and services over a specific period, contributing significantly to the growth of addiction therapeutics. Increased healthcare expenditure facilitates improved treatment accessibility, supports research and development initiatives, promotes the adoption of innovative therapies, and enhances comprehensive healthcare services for substance use disorders. As illustrated by the 2021–2030 National Health Expenditure (NHE) report from the Centers for Medicare & Medicaid Services in March 2022, the projected growth indicates an average annual increase of 5.1% in national health spending between 2021 and 2030, culminating in nearly $6.8 trillion. Notably, Medicare spending is expected to rise by 7.2% annually, while Medicaid spending will grow at a 5.6% annual rate from 2021 to 2030. This upsurge in healthcare expenditure serves as a driving force propelling the expansion of the addiction therapeutics market.

Prominent players within the addiction therapeutics market are actively pioneering innovative solutions, particularly drugs aimed at addressing cocaine use disorders (CUD), to cater to broader customer bases, amplify sales, and augment revenue streams. Drugs developed for CUD are specifically crafted medications intended to assist individuals grappling with cocaine addiction or dependence. An exemplar in this domain unfolded in January 2023 when Tempero Bio, a US-based biopharmaceutical firm, revealed the FDA's approval for TMP-301, its investigational candidate. This distinct product distinguishes itself as a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM), uniquely tailored to combat CUD. TMP-301's standout characteristics lie in its potency, selectivity, and oral availability, aimed at effectively curbing the hyperactive glutamate signaling associated with CUD.

Key industry players within the addiction therapeutics sector are strategically embracing partnerships to tackle nicotine addiction through smartphone interventions. Strategic partnerships denote collaborative endeavors wherein companies synergize their strengths and resources for mutual advantages and success. For instance, in January 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology giant, entered into a partnership with Alex Therapeutics, a Sweden-based entity specializing in digital therapeutics. The primary focus of this collaboration revolves around a digital therapeutic designed to combat nicotine addiction via smartphone intervention. Developed by Alex Therapeutics in alignment with the specifications of the German healthcare system alongside Pfizer Germany, the medical device represents the crux of this partnership. Leveraging Alex Therapeutics' AI-powered digital therapeutics platform, the Alex DTx Platform, this collaboration integrates evidence-based psychological approaches, notably Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT), with artificial intelligence. The platform offers personalized standalone treatments, aiming to address unmet needs among patients on a global scale. This strategic alliance signifies a concerted effort to revolutionize addiction therapeutics using digital interventions, potentially reshaping nicotine addiction treatments.

In March 2023, Indivior, a US-based pharmaceutical company, completed the acquisition of Opiant Pharmaceuticals Inc for an estimated $145 million. This strategic move is intended to enhance Indivior's portfolio in investigational opioid overdose therapy, fortify its scientific research capabilities, and further expand its offerings in the field of addiction treatment. Opiant Pharmaceuticals Inc., a US-based biopharmaceutical company specializing in medicines for addiction and drug overdose.

Major companies operating in the addictions therapeutics market report are Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Perrigo Company plc, Purdue Pharma L.P., Dr. Reddy's Laboratories Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Mallinckrodt Plc, Alkermes plc., Glenmark Pharmaceuticals Limited, Indivior plc., Lannett Company Inc., BioDelivery Sciences International Inc., Insys Therapeutics Inc., Camurus AB, Orexo AB, Elite Pharmaceuticals Inc., Alchem International Ltd, Avalo Therapeutics Inc., Braeburn Inc., Titan Pharmaceuticals Inc., BioCorRx Inc.

North America was the largest region in the addictions therapeutics market in 2023. The regions covered in the addictions therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the addictions therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key addiction therapeutics include medications such as buprenorphine, naltrexone, bupropion, disulfiram, nicotine replacement products, varenicline, and others. For instance, buprenorphine is a semi-synthetic narcotic analgesic used to mimic the effects of opioid medicines, helping to prevent withdrawal symptoms when an individual discontinues opioid use. Different types of addiction therapeutics cater to specific substance dependencies, including opioid addiction treatment, alcohol addiction treatment, nicotine addiction treatment, and treatments for other substance addictions. These therapeutic interventions can be implemented in various treatment centers, including inpatient treatment centers, residential treatment centers, and outpatient treatment centers. Distribution channels for addiction therapeutics encompass hospital pharmacies, medical stores, and others. These therapeutic solutions are accessible through public, private, and government healthcare settings, contributing to comprehensive and widespread addiction treatment and recovery efforts.

The addictions therapeutics market research report is one of a series of new reports that provides addictions therapeutics market statistics, including addictions therapeutics industry global market size, regional shares, competitors with a addictions therapeutics market share, detailed addictions therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the addictions therapeutics industry. This addictions therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The addiction therapeutics market consists of revenues earned by entities by providing cognitive behavioral therapy, contingency management for addiction, rational emotive behavior therapy (REBT), motivational interviewing, family therapy for addiction, facilitation therapy for addiction, eye movement desensitization and reprocessing (EMDR), dialectical behavior therapy, matrix model for addiction and person-centered therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The addiction therapeutics market also includes sales of suboxone, methadone, naltrexone, antidepressants, and acamprosate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.